Materials and methods

Nucleotidase activity assays for in vitro evaluation of inhibitory activity of the compounds
The potential inhibition mediated by the final compounds was evaluated either using the Green Malachite Phosphate Assay (Gentaur) as previously described [1] or by HPLC analysis of inosine content. Briefly, in 96-well plate, the purified recombinant human enzyme (cN-II full-length was obtained and purified beforehand according to a previously published procedure [1, 2] ) was added to a final concentration of 0.1 µM in 80 µl of buffer containing 50 mM imidazole pH 6.5, 500 mM NaCl and 10 mM MgCl 2 and the reaction was started by addition of the substrate (100 µM of IMP with an equimolar concentration of Mg
2+
) and incubated at 37 °C for 3 min and 30 s. Then, the reaction was quenched either by adding Green Malachite reagent or perchloric acid (PCA) 10%. With the green malachite reagent, the inorganic phosphate was quantified by measuring the absorbance at 630 nm using a Tecan plate reader (Sunrise) and compared with a 0-50 µM phosphate calibration curve. When precipitation occurs with this reagent, the reaction was stopped with PCA 10% and the inosine and IMP contents were quantified by HPLC (Waters Alliance) using a
Partisphere 5-SAX column (AIT) and 10 mM ammonium phosphate buffer pH 5.5 as mobile phase. All compounds were dissolved in water and assayed in the concentrations range varying from 0 to 2 mM. Results are expressed as the average (± SD) of three independent experiments.
Molecular docking studies
Molecular docking was carried out with the GOLD 5.2 program (Genetic Optimization for Ligand Docking) from CCDC Software Limited [3] . All derivatives were first s3 modelled using the VegaZZ molecular modelling program [4] and the atomic charges were assigned using the Gasteiger-Marsili empirical atomic partial charges [5] . The potential energy of all compounds was minimized using 500 steps of steepest descent followed by 5,000 steps of conjugate gradient (tolerance of 0.01 kcal/mol. Å).
Docking was performed on the cN-II crystal structure solved in presence of IMP (PDB 2XCW) by applying 50 genetic algorithm runs for conformational poses searching with a radius of 12 Å around the target atom, Mg 2+ ion (located in the substrate binding site). Structural water molecules present in the crystal structure and near the IMP binding site were retained and allowed to contribute with a 2 Å cut-off of translational and rotational freedom. Docking poses were analysed by the clustering method (complete linkage) from the rmsd matrix of ranking solutions. Solutions were classified according to their respective scores calculated by the Gold score scoring function. Structural analysis and visualization of docking poses was achieved with the PyMOL Molecular Graphics System (version 1.3, Schrödinger, LLC).
Description of general methods for chemical synthesis of the ß-hydroxy-
phosphonate analogues may be gleaned from the literature [2, 6] .
furanose [6] used as starting material was obtained according to previously published procedure.
(1-Azido-2,5-di-O-acetyl-3-O-benzoyl-6-deoxy-6-diethylphosphono)-β-ribo-(5S)-
hexofuranose (2)
To a solution of 1,2,5-tri-O-acetyl-3-O-benzoyl-6-deoxy-6-diethylphosphono-()- 133.8, 129.9, 129.8, 128.9, 128.8, 128.7, 128.5, 125 .9 (C-Ar), 119.2 (C=CH), 89.7 (C-1'), 84.5 (d, J = 9.7 Hz, C-4'), 74.3 (C-2'), 70.6 (C-3'), 67.6 (C-5'), 62. The azido sugar 2 (204 mg, 0.40 mmol) was dissolved in DMF (10 mL/mmol), then phenyl acetylene (176 µL, 1.6 mmol) and Cp*RuCl(PPh 3 ) 2 (16 mg, 0.02 mmol) were added and the reaction mixture was heated at 75°C overnight. The development of reaction was followed by TLC, after complete consumption of 2, the solvent was removed. 
6-Deoxy-6-diethylphosphono-1-(4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-β-Dallofuranose (4b)
Treatment of compound 3b (313 mg, 0.49 mmol) following general procedure D gave rise to the expected derivative 4b as white solid (219 mg, 99%). 
Rf (CH
3-O-Benzoyl-6-deoxy-2,5-O-diacetyl-6-diethylphosphono-1-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-β-D-allofuranose (3c)
Treatment of compound 2 (346 mg, 0.67 mmol) following general procedure A gave rise to the expected derivative 3c as a white oil (357 mg, 82%). Hz, C-4'), 74.5 (C-3'), 70.9 (C-2'), 67.9 (C-5'), 62. 
6-Deoxy-6-diethylphosphono-1-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-β-Dallofuranose (4c)
Treatment of compound 3c (337 mg, 0.52 mmol) following general procedure D gave rise to the expected derivative 4c as a white solid (214 mg, 90%). 634.1967.
6-Deoxy-6-diethylphosphono-1-(4-(fluorophenyl)-1H-1,2,3-triazol-1-yl)-β-Dallofuranose (4e)
Treatment of compound 3e (204 mg, 0.32 mmol) following general procedure D gave rise to the expected derivative 4e as a white solid (124 mg, 87%). 
Rf (CH
6-Deoxy-6-phosphono-1-(4-(fluorophenyl)-1H-1,2,3-triazol-1-yl)-β-D-allofuranose disodium salt (1e)
Treatment of compound 4e (88 mg, 0.20 mmol) following general procedure E gave rise to the expected derivative 1e as a white solid (79 mg, 91%). 
Rf (iPrOH/NH
3-O-Benzoyl-6-deoxy-2,5-O-diacetyl-6-diethylphosphono-1-(4-(3,5-bis(trifluoromethyl)pheny)-1H-1,2,3-triazol-1-yl)-β-D-allofuranose (3f)
Treatment of compound 2 (272 mg, 0.53 mmol) following general procedure A gave rise to the expected derivative 3f as a black solid (293 mg, 74%). 132.7, 132.4, 132.3, 129.9, 128.9, 125 .9 (C-Ar), 123. 
3-O-Benzoyl-6-deoxy-2,5-di-O-acetyl-6-diethylphosphono-1-(4-(4-(dimethylamino) phenyl)-1H-,1,2,3-triazol-1-yl)-β-D-allofuranose (3g)
Treatment of compound 2 (328 mg, 0.64 mmol) following general procedure A gave rise to the expected derivative 3g as an orange solid (370 mg, 88%). 2H, H-Ar), 7.37 (dd, J = 7.7, 1.1 Hz, 1H, H-Ar), 7.14 (t, J = 7.7 Hz, 1H, H-Ar), 6.75 (dd, J = 15.8, 7.9 Hz, 2H, 6.26 (d, J = 4.7 Hz, 1H, 6.07 (t, J = 5.0 Hz, 1H, s20 H-2'), 1H, 5.52 (ddd, J = 18.6, 6.7, 4.0 Hz, 1H, 4.78 (t, J = 4.1 Hz, 1H, 2H, 2.24 (dddd, J = 41.2, 19.2, 15.5, 6 2, 133.9, 129.9, 129.5, 128.8, 119.6 (C=CH), 117.7, 116.9, , 89.9 (C-1'), 84.5 (d, J = 9.6 Hz, C-4'), 74.4 (C-2'), 70.8 (C-3'), 67.7 (C-5'), 62.4, 62.3 (2d, J = 6.5 Hz, 7.50 (dd, J = 7.8, 1. 4 Hz, 1H, 1H, 1H, HAr), 6.61 (t, J = 7.4 Hz, 1H, 6.15 (d, J = 7.0 Hz, 1H, NH 2 4.54 (m, 1H, 4.28 (t, J = 3.9 Hz, 1H, 4.20 (ddd, J = 13.1, 8.9, 4.5 Hz, 1H, 1.83 (dddd, J = 23.9, 16.3, 14.9, 6.8 Hz, 2H, 6'') . 13C NMR (100 MHz, 89.9 (C-1'), 84.6 (d, J = 9.6 Hz, C-4'), 74.5 (C-3'), 70.9 (C-2'), 67.8 (C-5'), 62.4, 62.3 (2d, J = 6. 169.4 (C=O, Ac), 165.1 (C=O, Bz), 148.7 (C=C), 146.9, 133.9, 129.9, 128.9, 128.8, 127 . 
Rf (CH
